Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.98 |
| ▸ | PGR | P06401 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTT | P42858 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 2/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425550 | 1.00 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL14656870 | 1.00 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL508890 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL94788 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL21497316 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL17517045 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL5330 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL16812894 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL14649335 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL17519899 | 0.97 | LMNA (0.96) | LMNANR3C1SMN1; SMN2HIF1APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) | 2023-06-15 | — | — | US | claimed |
| WO-2021226390-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2021-11-11 | — | — | WO | claimed |
| WO-2021226402-A1 | PROGESTOGEN FORMULATIONS FOR USE IN MODULATING A CYTOKINE STORM MEDIATOR | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2021-11-11 | — | — | WO | claimed |
| CN-113616660-A | Progestogen formulations and uses thereof | 深圳埃格林医药有限公司 | 2021-11-09 | — | — | CN | claimed |
| US-20210244678-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2021-08-12 | — | — | US | claimed |
| EP-3651746-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | Hera Health Solutions Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014076-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20190008792-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2019-01-10 | — | — | US | claimed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | disclosed |
| US-12274797-B2 | Bioerodible drug delivery implants | HERA HEALTH SOLUTIONS INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2003041741-A1 | METHOD OF PREVENTING OR TREATING BENIGN GYNAECOLOGICAL DISORDERS | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-05-22 | — | — | WO | disclosed |
| EP-1293210-A1 | Means and method for hormonal contraception | Pantarhei Bioscience B.V. (NL) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193356-A1 | Means and method for hormonal contraception | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-12-19 | — | — | US | disclosed |
| WO-2002094281-A1 | MEANS AND METHOD FOR HORMONAL CONTRACEPTION | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094277-A1 | MEANS AND METHOD FOR HORMONAL CONTRACEPTION | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | LMNA 796/4885NR3C1 5/4885SMN1; SMN2 2999/4885 |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | CD44, CSGALNACT1, ALG1 | LMNA 4323/4885NR3C1 1799/4885SMN1; SMN2 2637/4885 |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHBG, PGR, CYP17A1 | LMNA 847/4885NR3C1 42/4885SMN1; SMN2 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.